Phospholipase D regulates the size of skeletal muscle cells through the activation of mTOR signaling

Cell Communication and Signaling

Volumn 11, Issue 1, 2013, Pages

  Jaafar, Rami ^a   De Larichaudy, Joffrey ^a   Chanon, Stéphanie ^a   Euthine, Vanessa ^a   Durand, Christine ^a   Naro, Fabio ^b   Bertolino, Philippe ^c   Vidal, Hubert ^a   Lefai, Etienne ^a   Némoz, Georges ^a  

^a CarMeN   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

mTOR; Muscle hypertrophy; Muscle wasting; Myotubes; Phosphatidic acid; Phospholipase D

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; ADENOVIRUS VECTOR; ATROGIN 1; DEXAMETHASONE; GREEN FLUORESCENT PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MUSCLE PROTEIN; MUSCLE RING FINGER 1 PROTEIN; MYOSIN HEAVY CHAIN; PHOSPHOLIPASE D; PROTEIN KINASE B; S6 KINASE; TRANSCRIPTION FACTOR FKHRL1; UBIQUITIN PROTEIN LIGASE E3; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PHOSPHATIDIC ACID; PHOSPHOLIPASE D1; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GASTROCNEMIUS MUSCLE; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; METABOLISM; CHEMICALLY INDUCED;

ANIMALS; CELL SIZE; DEXAMETHASONE; MALE; MICE; MICE, INBRED BALB C; MULTIPROTEIN COMPLEXES; MUSCLE FIBERS, SKELETAL; MUSCULAR ATROPHY; PHOSPHATIDIC ACIDS; PHOSPHOLIPASE D; TOR SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880882397     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-11-55     Document Type: Article

References (45)

1. Characterization of two alternately spliced forms of phospholipase D1. Activation of the purified enzymes by phosphatidylinositol 4,5-bisphosphate, ADP-ribosylation factor, and Rho family monomeric GTP-binding proteins and protein kinase C-alpha. Hammond SM, Jenco JM, Nakashima S, Cadwallader K, Gu Q, Cook S, Nozawa Y, Prestwich GD, Frohman MA, Morris AJ, J Biol Chem 1997 272 3860 3868 10.1074/jbc.272.6.3860 9013646 (Pubitemid 27066898)
2. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Colley WC, Sung TC, Roll R, Jenco J, Hammond SM, Altshuller Y, Bar-Sagi D, Morris AJ, Frohman MA, Curr Biol 1997 7 191 201 10.1016/S0960-9822(97)70090-3 9395408 (Pubitemid 27164725)
3. Mammalian phospholipase D physiological and pathological roles. Peng X, Frohman MA, Acta Physiol (Oxf) 2011 204 219 226
4. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J, Science 2001 294 1942 1945 10.1126/science.1066015 11729323 (Pubitemid 33101594)
5. PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1. Fang Y, Park IH, Wu AL, Du G, Huang P, Frohman MA, Walker SJ, Brown HA, Chen J, Curr Biol 2003 13 2037 2044 10.1016/j.cub.2003.11.021 14653992 (Pubitemid 37502519)
6. mTOR signaling in growth control and disease. Laplante M, Sabatini DM, Cell 2012 149 274 293 10.1016/j.cell.2012.03.017 22500797
7. mTOR signaling: PLD takes center stage. Sun Y, Chen J, Cell Cycle 2008 7 3118 3123 10.4161/cc.7.20.6881 18927511
8. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Foster DA, Biochim Biophys Acta 2009 1791 949 955 10.1016/j.bbalip.2009.02.009 19264150
9. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Veverka V, Crabbe T, Bird I, Lennie G, Muskett FW, Taylor RJ, Carr MD, Oncogene 2008 27 585 595 10.1038/sj.onc.1210693 17684489 (Pubitemid 351158903)
10. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA, Mol Cell Biol 2009 29 1411 1420 10.1128/MCB.00782-08 19114562
11. Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect. Yoon MS, Sun Y, Arauz E, Jiang Y, Chen J, J Biol Chem 2011 286 29568 29574 10.1074/jbc.M111.262816 21737445
12. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Sun Y, Fang Y, Yoon MS, Zhang C, Roccio M, Zwartkruis FJ, Armstrong M, Brown HA, Chen J, Proc Natl Acad Sci U S A 2008 105 8286 8291 10.1073/pnas.0712268105 18550814 (Pubitemid 351904748)
13. Class III PI-3-kinase activates phospholipase D in an amino acid-sensing mTORC1 pathway. Yoon MS, Du G, Backer JM, Frohman MA, Chen J, J Cell Biol 2011 195 435 447 10.1083/jcb.201107033 22024166
14. Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1). Xu L, Salloum D, Medlin PS, Saqcena M, Yellen P, Perrella B, Foster DA, J Biol Chem 2011 286 25477 25486 10.1074/jbc.M111.249631 21622984
15. Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass. Goodman CA, Mayhew DL, Hornberger TA, Cell Signal 2011 23 1896 1906 10.1016/j.cellsig.2011.07.013 21821120
16. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD, Nat Cell Biol 2001 3 1014 1019 10.1038/ncb1101-1014 11715023 (Pubitemid 34428747)
17. The role of skeletal muscle mTOR in the regulation of mechanical load-induced growth. Goodman CA, Frey JW, Mabrey DM, Jacobs BL, Lincoln HC, You JS, Hornberger TA, J Physiol 2011 589 5485 5501 21946849
18. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, Richard-Bulteau H, Vignaud A, Baas D, Defour A, Freyssenet D, Tanti JF, Le-Marchand-Brustel Y, Ferrier B, Conjard-Duplany A, Romanino K, Bauche S, Hantai D, Mueller M, Kozma SC, Thomas G, Ruegg MA, Ferry A, Pende M, Bigard X, Koulmann N, Schaeffer L, Gangloff YG, J Cell Biol 2009 187 859 874 10.1083/jcb.200903131 20008564
19. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Bentzinger CF, Romanino K, Cloetta D, Lin S, Mascarenhas JB, Oliveri F, Xia J, Casanova E, Costa CF, Brink M, Zorzato F, Hall MN, Ruegg MA, Cell Metab 2008 8 411 424 10.1016/j.cmet.2008. 10.002 19046572
20. Phospholipase D is involved in myogenic differentiation through remodeling of actin cytoskeleton. Komati H, Naro F, Mebarek S, De Arcangelis V, Adamo S, Lagarde M, Prigent AF, Nemoz G, Mol Biol Cell 2005 16 1232 1244 10.1091/mbc.E04-06-0459 15616193 (Pubitemid 40349560)
21. PLD regulates myoblast differentiation through the mTOR-IGF2 pathway. Yoon MS, Chen J, J Cell Sci 2008 121 282 289 10.1242/jcs.022566 18198186 (Pubitemid 351356699)
22. Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes. Jaafar R, Zeiller C, Pirola L, Di Grazia A, Naro F, Vidal H, Lefai E, Nemoz G, J Biol Chem 2011 286 22609 22621 10.1074/jbc.M110.203885 21525000
23. Role of phospholipase C and D signalling pathways in vasopressin- dependent myogenic differentiation. Naro F, Donchenko V, Minotti S, Zolla L, Molinaro M, Adamo S, J Cell Physiol 1997 171 34 42 10.1002/(SICI)1097- 4652(199704)171:1<34::AID-JCP5>3.0.CO;2-I 9119890 (Pubitemid 27158326)
24. The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. Hornberger TA, Chu WK, Mak YW, Hsiung JW, Huang SA, Chien S, Proc Natl Acad Sci U S A 2006 103 4741 4746 10.1073/pnas.0600678103 16537399
25. The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions. O'Neil TK, Duffy LR, Frey JW, Hornberger TA, J Physiol 2009 587 3691 3701 10.1113/jphysiol.2009.173609 19470781
26. PLD1 rather than PLD2 regulates phorbol-ester-, adhesion-dependent and Fc{gamma}-receptor-stimulated ROS production in neutrophils. Norton LJ, Zhang Q, Saqib KM, Schrewe H, Macura K, Anderson KE, Lindsley CW, Brown HA, Rudge SA, Wakelam MJ, J Cell Sci 2011 124 1973 1983 10.1242/jcs.082008 21610093
27. Molecular mechanisms of N-formyl-methionyl-leucyl-phenylalanine-induced superoxide generation and degranulation in mouse neutrophils: phospholipase D is dispensable. Sato T, Hongu T, Sakamoto M, Funakoshi Y, Kanaho Y, Mol Cell Biol 2013 33 136 145 10.1128/MCB.00869-12 23109426
28. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Su W, Yeku O, Olepu S, Genna A, Park JS, Ren H, Du G, Gelb MH, Morris AJ, Frohman MA, Mol Pharmacol 2009 75 437 446 10.1124/mol.108.053298 19064628
29. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, Thomas AL, Armstrong MD, Arteaga CL, Lindsley CW, Brown HA, Nature Chem Biol 2009 5 108 117 10.1038/nchembio.140
30. Quantification of hormone-induced atrophy of large myotubes from C2C12 and L6 cells: atrophy-inducible and atrophy-resistant C2C12 myotubes. Sultan KR, Henkel B, Terlou M, Haagsman HP, Am J Physiol Cell Physiol 2006 290 650 C659 16176969
31. Mechanisms of glucocorticoid-induced myopathy. Schakman O, Gilson H, Thissen JP, J Endocrinol 2008 197 1 10 10.1677/JOE-07-0606 18372227 (Pubitemid 351566920)
32. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E, Glass DJ, Cell Metab 2007 6 376 385 10.1016/j.cmet.2007.09.009 17983583 (Pubitemid 350011998)
33. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Reid MB, Li YP, Respir Res 2001 2 269 272 10.1186/rr67 11686894 (Pubitemid 34189649)
34. TNF-alpha- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. De Larichaudy J, Zufferli A, Serra F, Isidori AM, Naro F, Dessalle K, Desgeorges M, Piraud M, Cheillan D, Vidal H, Lefai E, Nemoz G, Skelet Muscle 2012 2 2 10.1186/2044-5040-2-2 22257771
35. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL, FASEB J 2004 18 39 51 10.1096/fj.03-0610com 14718385 (Pubitemid 38076464)
36. Identification of ubiquitin ligases required for skeletal muscle atrophy. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ, Science 2001 294 1704 1708 10.1126/science.1065874 11679633 (Pubitemid 33104839)
37. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL, Cell Metab 2007 6 472 483 10.1016/j.cmet.2007.11.004 18054316 (Pubitemid 350163056)
38. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM, PLoS Biol 2009 7 38 10.1371/journal.pbio.1000038 19209957
39. Plasticity of human skeletal muscle: gene expression to in vivo function. Harridge SD, Exp Physiol 2007 92 783 797 10.1113/expphysiol.2006.036525 17631518 (Pubitemid 47283914)
40. Phospholipase D confers rapamycin resistance in human breast cancer cells. Chen Y, Zheng Y, Foster DA, Oncogene 2003 22 3937 3942 10.1038/sj.onc.1206565 12813467 (Pubitemid 36819667)
41. PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals. Ha SH, Kim DH, Kim IS, Kim JH, Lee MN, Lee HJ, Kim JH, Jang SK, Suh PG, Ryu SH, Cell Signal 2006 18 2283 2291 10.1016/j.cellsig.2006.05.021 16837165 (Pubitemid 44636169)
42. Mechanotransduction and the regulation of mTORC1 signaling in skeletal muscle. Hornberger TA, Int J Biochem Cell Biol 2011 43 1267 1276 10.1016/j.biocel.2011.05.007 21621634
43. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ, Cell 2010 142 531 543 10.1016/j.cell.2010.07.011 20723755
44. Activation of mTOR signaling by novel fluoromethylene phosphonate analogues of phosphatidic acid. Xu Y, Fang Y, Chen J, Prestwich GD, Bioorg Med Chem Lett 2004 14 1461 1464 10.1016/j.bmcl.2004.01.020 15006382 (Pubitemid 38299429)
45. Phospholipase D2 regulates endothelial permeability through cytoskeleton reorganization and occludin downregulation. Zeiller C, Mebarek S, Jaafar R, Pirola L, Lagarde M, Prigent AF, Nemoz G, Biochim Biophys Acta 2009 1793 1236 1249 10.1016/j.bbamcr.2009.04.001 19371764